STOCK TITAN

Acadia Pharmaceuticals Inc - ACAD STOCK NEWS

Welcome to our dedicated news page for Acadia Pharmaceuticals (Ticker: ACAD), a resource for investors and traders seeking the latest updates and insights on Acadia Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Acadia Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Acadia Pharmaceuticals's position in the market.

Rhea-AI Summary
Acadia Pharmaceuticals announces the establishment of the Rett Sibling Scholarship, offering 10 scholarships of $5,000 each to eligible siblings of individuals with Rett syndrome for the 2024-2025 academic year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.54%
Tags
none
-
Rhea-AI Summary
Acadia Pharmaceuticals to report Q3 financial results and host conference call
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.21%
Tags
earnings
-
Rhea-AI Summary
Acadia Pharmaceuticals grants inducement awards to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.21%
Tags
none
Rhea-AI Summary
Acadia Pharmaceuticals grants inducement awards to new employees under 2023 Inducement Plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Acadia Pharmaceuticals appoints Albert Kildani as Senior VP, Investor Relations and Corporate Communications
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.66%
Tags
management
-
Rhea-AI Summary
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) to participate in upcoming investor conferences.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.11%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.53%
Tags
none
-
Rhea-AI Summary
ACAD - Acadia Pharmaceuticals Inc. Reports Strong 2Q23 Financial Results with Net Product Sales of $165.2 Million, Expanded Licensing Agreement, and Positive Late-Stage Portfolio Progress
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.85%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.9%
Tags
none
Rhea-AI Summary
Acadia Pharmaceuticals Inc. has appointed Dr. Kevin R. Oliver as Senior Vice President, Chief Business Officer. Dr. Oliver will oversee all business development functions and will serve as a member of the company’s Executive Management Committee. His appointment comes at a pivotal time as Acadia aims to grow its portfolio of central nervous system assets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.4%
Tags
management
Acadia Pharmaceuticals Inc

Nasdaq:ACAD

ACAD Rankings

ACAD Stock Data

3.05B
109.92M
0.46%
99.38%
6.45%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
San Diego

About ACAD

acadia pharmaceuticals (nasdaq: acad) is a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in related central nervous system (cns) disorders. all of acadia's product candidates emanate from internal discoveries. we believe that they offer innovative therapeutic approaches that may provide significant advantages relative to current therapies. acadia’s history is rooted in science and strong leadership in cns research. our proprietary drug discovery platform has led to a portfolio of drug candidates with large unmet needs. since the beginning, we have been dedicated to discovering, developing and commercializing innovative therapies that improve the lives of patients suffering from such disorders. acadia is headquartered in san diego. the city represents the second largest biotechnology industry cluster in the united states, home to over 400 companies, as well as the salk institute for biological studies